膀胱肿瘤侵袭前沿的AMIGO2表达可预测根治性膀胱切除术后的无复发生存率和总生存率。
AMIGO2 expression at the invasive front of bladder cancer predicts recurrence-free and overall survival after radical cystectomy.
作者信息
Yamamoto Atsushi, Izutsu Runa, Seong Heekyung, Shimizu Ryutaro, Nishikawa Ryoma, Kimura Yusuke, Yamaguchi Noriya, Morizane Shuichi, Hikita Katsuya, Honda Masashi, Takenaka Atsushi, Okada Futoshi
机构信息
Division of Experimental Pathology, Department of Functional Morphology, Tottori University Faculty of Medicine, Yonago, Tottori 683-8503, Japan.
Division of Urology, Department of Surgery, Tottori University Faculty of Medicine, Yonago, Tottori 683-8503, Japan.
出版信息
Oncol Lett. 2025 May 13;30(1):339. doi: 10.3892/ol.2025.15085. eCollection 2025 Jul.
Bladder cancer is a leading cause of cancer-related mortality worldwide, partly due to the absence of reliable biomarkers for the accurate prediction of patient prognosis. Amphoterin-induced gene and open reading frame 2 (AMIGO2) expression is a prognostic factor in several types of cancer. The present study aimed to clarify whether AMIGO2 expression can predict the prognosis of patients with bladder cancer. This retrospective study included patients with primary bladder cancer who underwent radical cystectomy at Tottori University Hospital (Yonago, Japan) and its affiliated hospitals between January 2010 and December 2017. Tumor tissues and data were collected from 100 patients and immunohistochemical analysis was performed. The independent predictors in multivariate analysis were lymph node metastasis for recurrence-free survival (RFS), and AMIGO2 expression and pathological T stage for overall survival (OS). Furthermore, AMIGO2 expression was evaluated at the invasive tumor front, and it was revealed that AMIGO2 expression was an independent prognostic factor for both RFS and OS, in addition to lymph node metastasis for RFS. Ki-67 expression, a marker of cell proliferation that is also associated with poor prognosis in several types of cancer, was examined, and Ki-67 expression and lymph node metastasis were identified as independent prognostic factors in RFS, but not in OS. However, the co-expression of AMIGO2 and Ki-67 was identified as an independent prognostic factor for OS. In conclusion, AMIGO2 expression may be considered a novel biomarker for the identification of the risk of recurrence and reduced survival in patients with bladder cancer, and could be used as a rationale for initiating treatment, such as radiation therapy, chemotherapy or immunotherapy, after radical cystectomy.
膀胱癌是全球癌症相关死亡的主要原因之一,部分原因是缺乏可靠的生物标志物来准确预测患者的预后。双调蛋白诱导基因及开放阅读框2(AMIGO2)的表达是几种癌症的预后因素。本研究旨在阐明AMIGO2表达是否能预测膀胱癌患者的预后。这项回顾性研究纳入了2010年1月至2017年12月期间在鸟取大学医院(日本米子)及其附属医院接受根治性膀胱切除术的原发性膀胱癌患者。收集了100例患者的肿瘤组织和数据,并进行了免疫组织化学分析。多变量分析中的独立预测因素为无复发生存期(RFS)的淋巴结转移,以及总生存期(OS)的AMIGO2表达和病理T分期。此外,在浸润性肿瘤前沿评估了AMIGO2表达,结果显示,除了RFS的淋巴结转移外,AMIGO2表达是RFS和OS的独立预后因素。检测了Ki-67表达,它是一种细胞增殖标志物,在几种癌症中也与不良预后相关,结果发现Ki-67表达和淋巴结转移是RFS的独立预后因素,但不是OS的独立预后因素。然而,AMIGO2和Ki-67的共表达被确定为OS的独立预后因素。总之,AMIGO2表达可被视为一种新型生物标志物,用于识别膀胱癌患者的复发风险和生存期缩短情况,并可作为根治性膀胱切除术后启动放疗、化疗或免疫治疗等治疗的依据。